farnesol has been researched along with Lymphangiomyomatosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ehrlich, M; Gefen-Dor, C; Jacob-Hirsch, J; Kloog, Y; Makovski, V; Rechavi, G; Shai, B | 1 |
| Haklai, R; Kloog, Y; Makovski, V | 1 |
2 other study(ies) available for farnesol and Lymphangiomyomatosis
| Article | Year |
|---|---|
Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.
Topics: Angiomyolipoma; Cell Proliferation; Farnesol; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Interferon Regulatory Factor-7; Kidney; Lymphangioleiomyomatosis; Microarray Analysis; Monomeric GTP-Binding Proteins; Neuropeptides; Ras Homolog Enriched in Brain Protein; RNA, Small Interfering; Salicylates; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2014 |
Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cysteine; Farnesol; Lymphangioleiomyomatosis; Lymphocytes, Null; Mice; Mice, Nude; Monomeric GTP-Binding Proteins; Mutation; Neuropeptides; Phosphorylation; Ras Homolog Enriched in Brain Protein; ras Proteins; Rats; Ribosomal Protein S6 Kinases; Salicylates; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2012 |